Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell lines

Abstract excerpt

Drug resistance is an urgent problem to be solved in the treatment of non‑small‑cell lung cancer (NSCLC). Osimertinib is a third‑generation EGFR‑tyrosine kinase inhibitor, which can improve the efficacy and quality of life of patients; however, the inevitable resistance after long‑term use of osimertinib often leads to treatment failure. Cell lines are key tools for basic and preclinical studies. At present, few...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Lipids, and Metabolism
• Share to Cancer Mechanisms and Therapy
• Share to Circular RNAs in diseases